Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Baird

Showing results (731-740 of 784) with videos related to

Pageof 79
Sort By:
Environment International|November 6, 2013
Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort StudyAnne P Starling, Stephanie M Engel, Kristina W Whitworth, et al.
Molecular Cancer Therapeutics|April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial EvaluationJoo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
American Journal of Epidemiology|February 22, 2014
Perfluoroalkyl substances during pregnancy and validated preeclampsia among nulliparous women in the Norwegian Mother and Child Cohort StudyAnne P Starling, Stephanie M Engel, David B Richardson, et al.
ESMO Open|January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1C Vaklavas, M Oliveira, A C Armstrong, et al.
International Journal of Surgery (London, England)|June 27, 2024
Global assessment of military and civilian trauma systems integration: a scoping reviewMichael D Baird, Emad S Madha, Matthew Arnaouti, et al.
Nature Communications|June 10, 2022
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancerR C Coombes, P D Badman, J P Lozano-Kuehne, et al.
Leukemia|August 11, 2015
Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trialJ C Strefford, L Kadalayil, J Forster, et al.
Nature Communications|March 6, 2025
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclibR C Coombes, Sacha Howell, Simon R Lord, et al.
The Journal of Surgical Research|December 1, 2022
Military and Civilian Trauma System Integration: A Global Case SeriesGhassan T Alswaiti, Tamara J Worlton, Matthew Arnaouti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH TrialIseult M Browne, Javier Pascual, Rosalind J Cutts, et al.
Pageof 79

Showing results (731-740 of 784) with videos related to

Sort By:
Pageof 79
Environment International|November 6, 2013
Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort StudyAnne P Starling, Stephanie M Engel, Kristina W Whitworth, et al.
Molecular Cancer Therapeutics|April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial EvaluationJoo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
American Journal of Epidemiology|February 22, 2014
Perfluoroalkyl substances during pregnancy and validated preeclampsia among nulliparous women in the Norwegian Mother and Child Cohort StudyAnne P Starling, Stephanie M Engel, David B Richardson, et al.
ESMO Open|January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1C Vaklavas, M Oliveira, A C Armstrong, et al.
International Journal of Surgery (London, England)|June 27, 2024
Global assessment of military and civilian trauma systems integration: a scoping reviewMichael D Baird, Emad S Madha, Matthew Arnaouti, et al.
Nature Communications|June 10, 2022
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancerR C Coombes, P D Badman, J P Lozano-Kuehne, et al.
Leukemia|August 11, 2015
Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trialJ C Strefford, L Kadalayil, J Forster, et al.
Nature Communications|March 6, 2025
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclibR C Coombes, Sacha Howell, Simon R Lord, et al.
The Journal of Surgical Research|December 1, 2022
Military and Civilian Trauma System Integration: A Global Case SeriesGhassan T Alswaiti, Tamara J Worlton, Matthew Arnaouti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH TrialIseult M Browne, Javier Pascual, Rosalind J Cutts, et al.
Pageof 79